Enteric fever, an infection caused by Salmonella Typhi and Paratyphi, continues to be a significant health concern worldwide, particularly in developing countries. This article offers a comprehensive overview of recent advancements in the diagnosis and treatment of enteric fever.
Traditional methods of diagnosis, including blood culture, have limitations in sensitivity and specificity. Recent advancements, however, have resulted in more accurate diagnostic tools. The Typhidot test, for instance, has shown promising results due to its rapid diagnosis time and high sensitivity. Additionally, the introduction of Polymerase Chain Reaction (PCR) based assays has further enhanced the accuracy of diagnosis, allowing for the detection of the bacteria at a molecular level.
Antibiotic resistance has complicated the treatment of enteric fever. However, new developments have provided alternatives to conventional therapies. Fluoroquinolones, despite increasing resistance, remain a mainstay of treatment. The use of third-generation cephalosporins, such as ceftriaxone and cefixime, has also proven effective. Recently, azithromycin has emerged as a reliable option, particularly in areas with high levels of multi-drug resistance.
Vaccination plays a critical role in the management of enteric fever. The development of new vaccines, such as the Vi-polysaccharide and Ty21a vaccines, has shown significant potential in controlling the disease. These vaccines, administered orally or via injection, have demonstrated excellent safety profiles and efficacy in preventing enteric fever.
In conclusion, while enteric fever remains a global health issue, advancements in diagnostic techniques, treatment options, and vaccine development offer promising avenues for improved management of the disease. As healthcare professionals, it is crucial to stay updated on these advancements to provide the best possible care to our patients.
1.
New guidelines for radiation therapy for HPV-associated head and neck cancer
2.
Cancer mortality continuing to decline, says report
3.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
4.
There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.
5.
Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease Control
1.
Different Types of Blood Dyscrasias
2.
Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study
3.
Lymphomatoid Papulosis: What You Need to Know
4.
MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed
5.
Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Clinical Insights in Oncology
2.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
3.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
4.
Navigating the Complexities of Ph Negative ALL - Part XI
5.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation